Pepsinogen I antibody | 8003 (99/12)

100% Secure

Mouse anti Human Pepsinogen I

Product Type
Monoclonal Antibody
8003 (99/12)
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
7240-1009 E P* R 0.2 mg
Mouse anti Human pepsinogen 1 antibody, clone 8003 recognizes human Pepsinogen I, a zymogen or proenzyme secreted by chief cells in the stomach. It is cleaved to form pepsin both in an autocatalytic fashion and by pepsin itself. In humans there are two related forms of pepsin, Pepsinogen I (also known as pepsinogen A), and Pepsinogen II (also known as Pepsinogen B or progastricsin).

Mouse anti Human pepsinogen 1 antibody, clone 8003 has an affinity of 4 x 1010 l/mol human Pepsinogen I.

Product Details

Target Species
Product Form
Purified IgG - liquid
Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.09%Sodium Azide (NaN3)
Purified human pepsinogen 1.
Approx. Protein Concentrations
IgG concentration 0.5 mg/ml

Storage Information

Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
18 months from date of despatch.

More Information

For research purposes only

Applications of Pepsinogen I antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Immunohistology - Paraffin 1
  1. 1*This product requires antigen retrieval using heat treatment prior to staining of paraffin sections.Sodium citrate buffer pH 6.0 is recommended for this purpose.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using the appropriate negative/positive controls.

Secondary Antibodies Available

Description Product Code Pack Size Applications List Price Quantity
Goat anti Mouse IgG (H/L):Alk. Phos. (Multi Species Adsorbed) STAR117A 0.5 mg E WB
Goat anti Mouse IgG (H/L):DyLight®488 (Multi Species Adsorbed) STAR117D488GA 0.1 mg F IF
Goat anti Mouse IgG (H/L):DyLight®680 (Multi Species Adsorbed) STAR117D680GA 0.1 mg F WB
Goat anti Mouse IgG (H/L):DyLight®800 (Multi Species Adsorbed) STAR117D800GA 0.1 mg F IF WB
Goat anti Mouse IgG (H/L):FITC (Multi Species Adsorbed) STAR117F 0.5 mg F
Goat anti Mouse IgG (H/L):HRP (Multi Species Adsorbed) STAR117P 0.5 mg E WB
Goat anti Mouse IgG (Fc):FITC STAR120F 1 mg C F
Goat anti Mouse IgG (Fc):HRP STAR120P 1 mg E WB
Rabbit F(ab')2 anti Mouse IgG:RPE STAR12A 1 ml F
Rabbit F(ab')2 anti Mouse IgG:HRP (Human Adsorbed) STAR13B 1 mg C E P RE WB
Goat anti Mouse IgG:FITC (Rat Adsorbed) STAR70 0.5 mg F
Goat anti Mouse IgG:RPE (Rat Adsorbed) STAR76 1 ml F
Goat anti Mouse IgG:HRP (Rat Adsorbed) STAR77 0.5 mg C E P
Goat anti Mouse IgG/A/M:Alk. Phos. STAR87A 1 mg C E WB
Goat anti Mouse IgG/A/M:HRP (Human Adsorbed) STAR87P 1 mg E
Rabbit F(ab')2 anti Mouse IgG:Dylight®800 STAR8D800GA 0.1 mg F IF WB
Rabbit F(ab')2 anti Mouse IgG:FITC STAR9B 1 mg F

Product Specific References

References for Pepsinogen I antibody

  1. Ueyama, H. et al. (2010) Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma.
    Am J Surg Pathol. 34: 609-19.
  2. Genta, R.M. & Pusztaszeri, M. (2006) The gastric mucosa in gastric cancer patients in a low-incidence area.
    Eur J Gastroenterol Hepatol. 18 (10): 1085-93.
  3. Fujita, Y. et al. (2016) Incidence of lymphatic involvement in differentiated-type intramucosal gastric cancers as examined by endoscopic resection.
    Gastric Cancer. 19 (1): 192-7.
  4. Hidaka, Y. et al. (2013) Alteration in the Wnt/β-catenin signaling pathway in gastric neoplasias of fundic gland (chief cell predominant) type
    Hum Pathol. 44: 2438-48.
  5. Sakamoto, H. et al. (2011) Cell lineage dynamics in the process leading to intestinal metaplasia.
    J Gastroenterol. 46: 620-8.
  6. Nakajima, T. et al. (2016) Distribution of Lgr5-positive cancer cells in intramucosal gastric signet-ring cell carcinoma.
    Pathol Int. 66 (9): 518-23.
  7. Mamat O et al. (2016) Fundic gland differentiation of oncocytic/pancreatobiliary subtypes of pancreatic intraductal papillary mucinous neoplasms.
    Histopathology. Mar 17. [Epub ahead of print]
  8. Mitsuishi, T. et al. (2017) Clinicopathological characteristics of duodenal epithelial neoplasms: Focus on tumors with a gastric mucin phenotype (pyloric gland-type tumors).
    PLoS One. 12 (4): e0174985.
  9. Chiba, T. et al. (2016) Clinicopathological features of gastric adenocarcinoma of the fundic gland (chief cell predominant type) by retrospective and prospective analyses of endoscopic findings.
    Dig Endosc. 28 (7): 722-30.
  10. Nakajima, T. et al. (2016) Distribution of Lgr5-positive cancer cells in intramucosal gastric signet-ring cell carcinoma.
    Pathol Int. 66 (9): 518-23.
Op-in to our ecommunications and set your preferences to start receiving resources, protocols, product updates, special offers, and more.